David P Dutka
Overview
Explore the profile of David P Dutka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ring L, Abu-Omar Y, Kaye N, Rana B, Watson W, Dutka D, et al.
J Am Soc Echocardiogr
. 2019 Apr;
32(4):545-547.
PMID: 30954123
No abstract available.
2.
Giblett J, Clarke S, Dutka D, Hoole S
JACC Basic Transl Sci
. 2018 Sep;
1(4):267-276.
PMID: 30167515
Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury....
3.
Ring L, Abu-Omar Y, Kaye N, Rana B, Watson W, Dutka D, et al.
J Am Soc Echocardiogr
. 2018 May;
31(9):983-991.
PMID: 29804897
Background: The aim of this study was to determine whether assessment of left atrial (LA) function helps identify patients at risk for early deterioration during follow-up with mitral valve prolapse...
4.
Ring L, Dutka D, Boyd J, Parker K, Wendler O, Monaghan M, et al.
JACC Cardiovasc Imaging
. 2017 Aug;
11(3):510-512.
PMID: 28823743
No abstract available.
5.
Giblett J, Axell R, White P, Clarke S, McCormick L, Read P, et al.
Cardiovasc Diabetol
. 2016 Jul;
15:99.
PMID: 27431258
Background: Glucagon-like peptide-1 (7-36) amide (GLP-1) protects against stunning and cumulative left ventricular dysfunction in humans. The mechanism remains uncertain but GLP-1 may act by opening mitochondrial K-ATP channels in...
6.
McCormick L, Heck P, Ring L, Kydd A, Clarke S, Hoole S, et al.
Cardiovasc Diabetol
. 2015 Aug;
14:102.
PMID: 26253538
Background: Enhancement of myocardial glucose uptake may reduce fatty acid oxidation and improve tolerance to ischemia. Hyperglycemia, in association with hyperinsulinemia, stimulates this metabolic change but may have deleterious effects...
7.
McCormick L, Hoole S, White P, Read P, Axell R, Clarke S, et al.
JACC Cardiovasc Interv
. 2015 Feb;
8(2):292-301.
PMID: 25700752
Objectives: This study sought to determine whether pre-treatment with intravenous glucagon-like peptide-1 (GLP-1)(7-36) amide could alter myocardial glucose use and protect the heart against ischemic left ventricular (LV) dysfunction during...
8.
Kydd A, Khan F, Ring L, Pugh P, Virdee M, Dutka D
Eur J Heart Fail
. 2014 Oct;
16(11):1206-13.
PMID: 25302484
Aims: Optimal delivery of CRT requires appropriate patient selection and device implantation. Echocardiographic predictors of CRT response individually appear to enhance patient selection, but do not fully reflect the complex...
9.
Kydd A, Khan F, Watson W, Pugh P, Virdee M, Dutka D
JACC Heart Fail
. 2014 Jun;
2(3):205-12.
PMID: 24952685
Objectives: This study was conducted to assess the impact of left ventricular (LV) lead position on longer-term survival after cardiac resynchronization therapy (CRT). Background: An optimal LV lead position in...
10.
Ring L, Rana B, Wells F, Kydd A, Dutka D
JACC Cardiovasc Imaging
. 2014 Feb;
7(3):225-32.
PMID: 24529886
Objectives: The purpose of this study was to determine the clinical utility of left atrial (LA) functional indexes in patients with mitral valve prolapse (MVP) and mitral regurgitation (MR). Background:...